Abstract
In the fields of endocrinology and toxicology, there are ongoing debates about whether endocrine disrupting chemicals (EDCs) produce non-monotonic dose responses. This type of response is typically characterized by a U- or inverted U-shaped relationship between dose and effect. In a recent report, a US EPA panel concluded that non-monotonicity is observed for EDCs, but that these responses are not expected in vivo, and are not typically observed in apical endpoints, i.e. endpoints that are indicators of adverse effects. Here, we have analyzed the shapes of the dose response curves in an EPA report analyzing the effectiveness of the Endocrine Disruptor Screening Program (EDSP) Tier 1 assays. This report included the results of 11 guideline assays for each of 4 chemicals. We found indications of non-monotonic dose response curves (iNMDRCs) for 3 of the 4 coded chemicals. In total, 27% of assays with dose response data included at least one iNMDRC. When the endpoints from the 4 test chemicals with dose respo...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
